Narrative Update on Invivyd Price Target
Analysts have raised Invivyd’s price target from $3.00 to $5.67, citing updated forecasts and changes in market expectations.
What's in the News
- The U.S. FDA cleared Invivyd’s Investigational New Drug application, enabling advancement of the REVOLUTION clinical program for VYD2311, a monoclonal antibody candidate for COVID-19 prevention (Key Developments).
- Invivyd plans to initiate pivotal clinical trials, including the DECLARATION and LIBERTY studies. The company aims to begin by year-end 2025 and report top-line results in mid-2026 (Key Developments).
- The company received consensus recommendation for a clinical study to evaluate the effects of monoclonal antibody therapy on Long COVID. VYD2311 leverages the same antibody backbone as their previously authorized products (Key Developments).
- Positive in vitro neutralization data reported for PEMGARDA® (pemivibart) against the dominant XFG COVID-19 variant, reinforcing the product’s emergency use authorization in immunocompromised patients (Key Developments).
- Invivyd completed a follow-on equity offering and raised approximately $50 million to support its development programs (Key Developments).
Valuation Changes
- Fair Value: Increased from $3 to $5.67, indicating a substantial rise in valuation expectations.
- Discount Rate: Slightly increased from 6.78% to 6.79%.
- Revenue Growth: Reduced significantly from 96.3% to 79.9%.
- Net Profit Margin: Declined from 28.6% to 16.1%.
- Future P/E: Rose sharply from 7.2x to 19.3x.
Have other thoughts on Invivyd?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeDisclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.